Home › NDC Lookup › RxCUI directory › RxCUI 2698564

Nilotinib 71 MG Oral Tablet — RxCUI 2698564

RxNorm drug concept · Semantic clinical drug
RxCUI 2698564 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2698564
Official nameNilotinib 71 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asnilotinib 71 MG (equivalent to nilotinib tartrate 91.14 MG) Oral Tablet
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)15 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Nilotinib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats Ph+ CML, a type of chronic myeloid leukemia. It is used in newly diagnosed patients and in those whose earlier treatment, such as imatinib, stopped working or caused prob...
  • Take it by mouth twice a day, about 12 hours apart. Tasigna and nilotinib capsules must be taken with no food 2 hours before and 1 hour after. Danziten and Cavhanza can be taken wi...
  • Not on your own. Danziten and Cavhanza do not convert milligram for milligram with other nilotinib products, and a mix-up could mean too much or too little drug. Always check with...
  • Rash, itching, headache, nausea, tiredness, and constipation or diarrhea are common. Regular blood tests will track your blood counts and liver and other labs. Call right away for...
📖 Read our full Nilotinib guide →

🕸️ Concept Web — How Nilotinib 71 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Nilotinib 71 MG Oral Tablet RxCUI 2698564

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Nilotinib 662281
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Danziten 2698565
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Nilotinib Oral Tablet 2698563
    • Nilotinib Oral Product 1158944
    • Nilotinib Pill 1158945
    • Nilotinib Oral Tablet [Danziten] 2698569
    • Danziten Oral Product 2698567
    • Danziten Pill 2698568
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Nilotinib 71 MG SCDC · 2698562
  • Nilotinib Oral Tablet SCDF · 2698563
  • Nilotinib Oral Product SCDG · 1158944
  • Nilotinib Pill SCDG · 1158945

Brand-Name Concepts

  • Nilotinib 71 MG Oral Tablet [Danziten] SBD · 2698570
  • Nilotinib 71 MG [Danziten] SBDC · 2698566
  • Nilotinib Oral Tablet [Danziten] SBDF · 2698569
  • Danziten Oral Product SBDG · 2698567
  • Danziten Pill SBDG · 2698568
  • Danziten BN · 2698565

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 2698564 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
24338-0154-01 4 CARTON in 1 CARTON (24338-154-01) / 2 BLISTER PACK in 1 C... DANZITEN Azurity Pharmaceuticals, Inc. 2024-11-30
24338-0155-01 4 CARTON in 1 CARTON (24338-155-01) / 2 BLISTER PACK in 1 C... DANZITEN Azurity Pharmaceuticals, Inc. 2024-11-30
Observed labelers: Azurity Pharmaceuticals, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.